Illustration of the depot-specific targeting of fat by cationic nanomaterials. Image: Nicoletta Barolini/Columbia University.
Illustration of the depot-specific targeting of fat by cationic nanomaterials. Image: Nicoletta Barolini/Columbia University.

Researchers have long been working on how to treat obesity, a serious condition that can lead to hypertension, diabetes, chronic inflammation and cardiovascular diseases. Studies have also revealed a strong correlation between obesity and cancer—recent data show that smoking, drinking alcohol and obesity are the biggest contributors to cancer worldwide.

The development of fat cells, which are produced from a tiny fibroblast-like progenitor, involves not only activating the fat cells’ specific genes but also growing them by storing lipids (adipocytes and adipose tissue). In fact, lipid storage is the defining function of a fat cell. But the storage of too much lipid can make fat cells unhealthy and lead to obesity.

The ability to target fat cells and safely uncouple unhealthy fat formation from healthy fat metabolism would be the answer to many peoples’ prayers. A major challenge in obesity treatment is that fat tissue, which is not continuous in the body but is found piece-by-piece in ‘depots’, has been difficult to target in a depot-specific manner, pinpointed at precise locations.

There are two main kinds of fat: visceral fat, which surrounds the stomach, liver and intestines; and subcutaneous fat, which is found under the skin anywhere in the body. Visceral fat produces potbellies; subcutaneous fat can create chin jowls, arm fat, etc. To date, there has been no way to specifically treat visceral adipose tissue. And current treatments for subcutaneous fat, such as liposuction, are invasive and destructive.

Now, two studies from researchers at Columbia Engineering and Columbia University Irving Medical Center (CUIMC) may have the answer to targeting fat cells depots specifically and healthily. The papers demonstrate a new method to treat obesity with cationic nanomaterials that can target specific areas of fat and inhibit the unhealthy storage of enlarged fat cells. These materials remodel fat rather than destroying it, unlike, for example, liposuction.

The first paper, published in Nature Nanotechnology, focuses on visceral adiposity, or belly fat. The second paper, published in Biomaterials, focuses on fat underneath the skin as well as the chronic inflammation associated with obesity.

The team of researchers, led by Li Qiang, associate professor of pathology and cell biology at CUIMC, and Kam Leong, professor of biomedical engineering and of systems biology at CUIMC, recognized that adipose tissue contains large amounts of negatively charged extracellular matrix (ECM) for holding fat cells. They thought that this negatively charged ECM network might provide a highway system of sorts for positively charged molecules. So they took a positively charged polyamidoamine (PAMAM) nanomaterial known as PAMAM generation 3 (P-G3) and injected it into obese mice. The P-G3 quickly spread throughout the tissue and the team was excited that their method to specifically target visceral fat worked.

And then something intriguing happened: P-G3 shut off the lipid storage program in fat cells and the mice lost weight. This was totally unexpected, given the well-established function of P-G3 in neutralizing negatively charged pathogens, such as DNA/RNA cell debris, to alleviate inflammation.

“Our approach is unique – it departs from the pharmacological or surgical approaches,” says Qiang, who specializes in obesity and adipocyte biology. “We used cationic charge to rejuvenate healthy fat cells, a technique no one has ever used to treat obesity. I think this novel strategy will open the door to healthier and safer reduction of fat.”

In these two studies, the researchers discovered that the cationic material P-G3 could do an intriguing thing to fat cells – while it helped new fat cell formation, it also uncoupled lipid storage from the housekeeping functions of fat cells. And because P-G3 inhibited the unhealthy lipid storage of enlarged fat cells, the mice had more metabolically healthy, young, small fat cells like those found in newborns and athletes. The researchers found that this uncoupling function of P-G3 also holds true in human fat biopsies, signifying the potential for translation into humans.

“With P-G3, fat cells can still be fat cells, but they can't grow up,” explained Leong, a pioneer in using polycations to scavenge pathogens. “Our studies highlight an unexpected strategy to treat visceral adiposity and suggest a new direction of exploring cationic nanomaterials for treating metabolic diseases.”

Now that they can selectively target visceral fat, Leong and Qiang envision several applications. The Biomaterials paper demonstrates a simple approach that could be used for aesthetic purposes; like Botox, P-G3 can be locally injected into a specific, subcutaneous fat depot. The investigators, who have patents pending, are now engineering P-G3 into various derivatives to improve the efficacy, safety and depot specificity.

What the researchers are particularly excited about is developing P-G3 into a platform that can deliver drugs and gene therapies specifically to a given fat depot, which could repurpose many drugs from systemic safety concerns. One example is thiazolidinediones (TZDs), a potent but unsafe drug that is a strong modulator of fat and used to treat type 2 diabetes – but it has been linked to heart failure and is banned in several countries.

“We’re very excited to discover that cationic charge is the secret to targeting adipose tissue,” Qiang said. “Now we can shrink fat in a depot-specific manner – anywhere we want – and in a safe way without destroying fat cells. This is a major advance in treating obesity.”

This story is adapted from material from Columbia Engineering, with editorial changes made by Materials Today. The views expressed in this article do not necessarily represent those of Elsevier. Link to original source.